In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Erika Lorena Cedillo-GutiérrezFacultad de Química, Universidad Nacional Autónoma de México, Av. Universidad 3000, Circuito Exterior s/n, CU, Ciudad de México C.P. 04510, Mexico.
Adrián Espinoza-GuillénFacultad de Química, Universidad Nacional Autónoma de México, Av. Universidad 3000, Circuito Exterior s/n, CU, Ciudad de México C.P. 04510, Mexico.
Luis Felipe Hernández-AyalaFacultad de Química, Universidad Nacional Autónoma de México, Av. Universidad 3000, Circuito Exterior s/n, CU, Ciudad de México C.P. 04510, Mexico.ORCID 0000-0002-3387-763X Esther Reveles-AyalaLaboratorio de Biomedicina Interdisciplinaria, Centro Interdisciplinario de Biociencias Aplicadas a la Salud, Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Santiago de Querétaro C.P. 76230, Mexico.
Marcos Flores-ÁlamoEdificio H Mario Molina, Circuito Mario de la Cueva, Esquina Circuito de la Investigación Científica, CU, Ciudad de México C.P. 04510, Mexico.ORCID 0000-0002-2996-7616 Luis Antonio Ortiz-FradeCentro de Investigación y Desarrollo Tecnológico en Electroquímica (CIDETEQ), Parque Tecnológico Quéretaro s/n, Sanfandila, Pedro Escobedo C.P. 76703, Mexico.
Carmen MejíaLaboratorio de Biomedicina Interdisciplinaria, Centro Interdisciplinario de Biociencias Aplicadas a la Salud, Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Santiago de Querétaro C.P. 76230, Mexico.ORCID 0000-0002-3210-4213 Lena Ruiz-AzuaraFacultad de Química, Universidad Nacional Autónoma de México, Av. Universidad 3000, Circuito Exterior s/n, CU, Ciudad de México C.P. 04510, Mexico.ORCID 0000-0003-3035-4507 Funding
PAIP-UNAM 5000-9047PAPIIT-UNAM IN226126Ph.D. scholarship-SECIHTI No. 607665
6 · The paper itselfAbstract
This study addresses the development of nickel(II) complexes with potential antiproliferative activity. Two novel hydrogenated Schiff base ligands (N
Indexed as
Antineoplastic AgentsCaspase 3Coordination ComplexesKetonesNickelReactive Oxygen SpeciesApoptosisCell ProliferationHeLa CellsHumansLigandsOxidation-ReductionSchiff BasesAntineoplastic AgentsCaspase 3Coordination ComplexesKetonesLigandsNickelReactive Oxygen SpeciesSchiff Basesantiproliferative activityapoptosisfluorinated ligandsHydrogenated Schiff basesmixed chelate complexesnickel(II)redox potentialβ-diketones
Identifiers
PMID42589259
PMCPMC13465113
What OpenQuestion holds
Textmetadata
Read underepoch 390